11.34

4.04% 0.44

Novocure Ltd (NVCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NVCR? Forum Prognose

Schlusskurs vom Vortag:

$10.90

Offen:

$10.97

24-Stunden-Volumen:

1.37M

Relative Volume:

0.87

Marktkapitalisierung:

$1.27B

Einnahmen:

$577.74M

Nettoeinkommen (Verlust:

$-149.78M

KGV:

-8.10

EPS:

-1.4

Netto-Cashflow:

$-78.21M

1W Leistung:

-0.79%

1M Leistung:

-35.57%

6M Leistung:

-46.93%

1J Leistung:

-38.30%

1-Tages-Spanne:

$10.90

$11.35

1-Wochen-Bereich:

$10.87

$11.69

52-Wochen-Spanne:

$10.87

$34.13

Novocure Ltd Stock (NVCR) Company Profile

Firmenname

Novocure Ltd

Sektor

Healthcare (1159)

Branche

Medical Devices (150)

Telefon

44 (0)15 3475 6700

Adresse

NO. 4 THE FORUM, ST. HELIER

Mitarbeiter

1,488

Twitter

@novocure

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

NVCR's Discussions on Twitter

Vergleichen Sie NVCR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCR Novocure Ltd	11.34	1.22B	577.74M	-149.78M	-78.21M	-1.40
ABT Abbott Laboratories	131.02	228.63B	43.11B	13.98B	6.78B	7.98
BSX Boston Scientific Corp	102.64	152.25B	18.49B	2.51B	3.23B	1.68
SYK Stryker Corp	376.61	144.00B	23.82B	2.92B	4.02B	7.55
MDT Medtronic Plc	92.08	118.82B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	76.93	45.89B	5.69B	4.14B	577.90M	6.96

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-07-08	Eingeleitet	Ladenburg Thalmann	Buy
2024-12-02	Hochstufung	Evercore ISI	In-line → Outperform
2024-10-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-08	Hochstufung	Piper Sandler	Neutral → Overweight
2023-08-04	Eingeleitet	SVB Securities	Outperform
2023-07-31	Hochstufung	Evercore ISI	Underperform → In-line
2023-06-07	Hochstufung	Wedbush	Underperform → Neutral
2023-05-16	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2023-01-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-01-05	Bestätigt	H.C. Wainwright	Buy
2022-11-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-24	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-05	Herabstufung	Evercore ISI	In-line → Underperform
2022-05-16	Eingeleitet	H.C. Wainwright	Buy
2022-02-08	Eingeleitet	Loop Capital	Buy
2022-02-02	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-20	Hochstufung	Truist	Hold → Buy
2022-01-03	Hochstufung	Evercore ISI	Underperform → In-line
2021-07-01	Herabstufung	Mizuho	Buy → Neutral
2021-04-14	Herabstufung	Wedbush	Neutral → Underperform
2021-01-25	Bestätigt	Piper Sandler	Overweight
2020-09-23	Eingeleitet	Northland Capital	Outperform
2020-09-18	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-17	Herabstufung	Truist	Buy → Hold
2020-06-01	Fortgesetzt	Oppenheimer	Perform
2020-05-01	Herabstufung	Oppenheimer	Outperform → Perform
2020-04-09	Herabstufung	Evercore ISI	In-line → Underperform
2020-03-05	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-29	Hochstufung	SunTrust	Hold → Buy
2019-07-26	Herabstufung	JP Morgan	Overweight → Neutral
2019-07-26	Herabstufung	Wedbush	Outperform → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2018-11-02	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-07-16	Eingeleitet	Evercore ISI	Outperform
2018-04-18	Bestätigt	Mizuho	Buy
2018-02-23	Bestätigt	Mizuho	Buy
2017-05-24	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-07-29	Bestätigt	Wedbush	Outperform
2016-01-19	Eingeleitet	Barclays	Underweight
2015-12-02	Eingeleitet	Deutsche Bank	Hold

Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

Aug 12, 2025

Statistical indicators supporting NovoCure Limited’s strengthFree Watchlist for Low Risk High Return - Newser

Aug 12, 2025

Aug 11, 2025

Novocure stock hits 52-week low at 10.88 USD By Investing.com - Investing.com Nigeria

Aug 11, 2025

Novocure stock hits 52-week low at 10.88 USD - Investing.com

Aug 11, 2025

Aug 09, 2025

NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest

Aug 09, 2025

Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser

Aug 09, 2025

Aug 08, 2025

Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser

Aug 08, 2025

Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser

Aug 08, 2025

Aug 07, 2025

NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks

Aug 07, 2025

Aug 06, 2025

Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser

Aug 06, 2025

Aug 04, 2025

How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser

Aug 04, 2025

Aug 03, 2025

How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News

Aug 03, 2025

What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News

Aug 03, 2025

Aug 02, 2025

How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News

Aug 02, 2025

Aug 01, 2025

Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser

Aug 01, 2025

Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st

Aug 01, 2025

NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st

Aug 01, 2025

NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World

Aug 01, 2025

Jul 31, 2025

Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks

Jul 31, 2025

NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest

Jul 31, 2025

NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha

Jul 31, 2025

Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser

Jul 31, 2025

Jul 30, 2025

Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser

Jul 30, 2025

Why NovoCure Stock Is Cratering Today - Mitrade

Jul 30, 2025

Jul 29, 2025

NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 29, 2025

Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser

Jul 29, 2025

Jul 28, 2025

What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News

Jul 28, 2025

Top 3 Health Care Stocks That May Explode In July - inkl

Jul 28, 2025

Jul 27, 2025

Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World

Jul 27, 2025

NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest

Jul 27, 2025

Jul 26, 2025

NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st

Jul 26, 2025

Jul 25, 2025

NovoCure: Q2 Earnings Snapshot - Norwalk Hour

Jul 25, 2025

NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha

Jul 25, 2025

Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jul 25, 2025

Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus

Jul 25, 2025

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛

Jul 25, 2025

NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional

Jul 25, 2025